blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3939659

EP3939659 - DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  27.10.2023
Database last updated on 29.06.2024
FormerRequest for examination was made
Status updated on  17.12.2021
FormerThe international publication has been made
Status updated on  19.09.2020
Most recent event   Tooltip27.10.2023Application deemed to be withdrawnpublished on 29.11.2023  [2023/48]
Applicant(s)For all designated states
Showa University
1-5-8 Hatanodai Shinagawa-ku
Tokyo 142-8555 / JP
For all designated states
Biogen MA Inc.
225 Binney Street
Cambridge, MA 02142 / US
[2022/27]
Former [2022/03]For all designated states
Showa University
1-5-8 Hatanodai Shinagawa-ku
Tokyo 142-8555 / JP
For all designated states
TMS Co., Ltd.
1-23-3-5F, Miyamachi
Fuchi-shi, Tokyo 183-0023 / JP
Inventor(s)01 / SHIBATA, Keita
c/o Showa University, School of Pharmacy,
Division of Pharmacology, Department of
Pharmacology, Toxicology and Therapeutics, 1-5-8
Hatanodai, Shinagawa-ku
Tokyo 142-8555 / JP
02 / SHINOUCHI, Ryosuke
c/o Showa University, School of Pharmacy,
Division of Pharmacology, Department of
Pharmacology, Toxicology and Therapeutics, 1-5-8
Hatanodai, Shinagawa-ku
Tokyo 142-8555 / JP
03 / HASHIMOTO, Terumasa
c/o Showa University, School of Pharmacy,
Division of Pharmacology, Department of
Pharmacology, Toxicology and Therapeutics, 1-5-8
Hatanodai, Shinagawa-ku
Tokyo 142-8555 / JP
04 / NOBE, Koji
c/o Showa University, School of Pharmacy,
Division of Pharmacology, Department of
Pharmacology, Toxicology and Therapeutics, 1-5-8
Hatanodai, Shinagawa-ku
Tokyo 142-8555 / JP
[N/P]
Former [2022/03]01 / SHIBATA, Keita
Tokyo 142-8555 / JP
02 / SHINOUCHI, Ryosuke
Tokyo 142-8555 / JP
03 / HASHIMOTO, Terumasa
Tokyo 142-8555 / JP
04 / NOBE, Koji
Tokyo 142-8555 / JP
Representative(s)Beck Greener LLP
Fulwood House
12 Fulwood Place
London WC1V 6HR / GB
[2022/03]
Application number, filing date20771088.012.03.2020
[2022/03]
WO2020JP10967
Priority number, dateJP2019004467012.03.2019         Original published format: JP 2019044670
[2022/03]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020184691
Date:17.09.2020
Language:JA
[2020/38]
Type: A1 Application with search report 
No.:EP3939659
Date:19.01.2022
Language:EN
[2022/03]
Search report(s)International search report - published on:JP17.09.2020
(Supplementary) European search report - dispatched on:EP17.11.2022
ClassificationIPC:A61K31/407, A61K31/502, A61K31/352, A61P9/10, A61P13/12, A61P25/00, A61P25/02, A61P27/02, A61P3/10
[2022/51]
CPC:
A61P9/10 (EP); A61K31/407 (EP,KR,US); A61K31/352 (EP);
A61K31/502 (EP); A61P13/12 (EP,KR,US); A61P25/00 (EP,KR);
A61P25/02 (EP,US); A61P27/02 (EP); A61P3/10 (EP) (-)
Former IPC [2022/03]A61P9/10, A61P13/12, A61P25/00, A61P25/02, A61P27/02, A61K31/407, A61K31/502
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/03]
TitleGerman:ARZNEIMITTEL UND VERFAHREN ZUR BEHANDLUNG ODER VORBEUGUNG VON KOMPLIKATIONEN BEI DIABETES UNTER VERWENDUNG DIESES ARZNEIMITTELS[2022/03]
English:DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG[2022/03]
French:MÉDICAMENT ET PROCÉDÉ DE TRAITEMENT OU DE PRÉVENTION DE COMPLICATIONS DU DIABÈTE, À L'AIDE DUDIT MÉDICAMENT[2022/03]
Entry into regional phase14.09.2021Translation filed 
14.09.2021National basic fee paid 
14.09.2021Search fee paid 
14.09.2021Designation fee(s) paid 
14.09.2021Examination fee paid 
Examination procedure14.09.2021Examination requested  [2022/03]
17.06.2023Application deemed to be withdrawn, date of legal effect  [2023/48]
10.07.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2023/48]
Fees paidRenewal fee
16.02.2022Renewal fee patent year 03
21.03.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XD]JP2004224738  (TTC KK) [XD] 1-4,15,16 * the whole document *;
 [Y]EP2452679  (UNIV TOKYO NAT UNIV CORP [JP], et al) [Y] 1-16 * the whole document *;
 [Y]  - SUZUKI ERIKO ET AL, "Soluble Epoxide Hydrolase As An Anti-Inflammatory Target Of The Thrombolytic Stroke Drug Candidate Smtp-7", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 122, no. 21, doi:10.1182/BLOOD.V122.21.2336.2336, ISSN 0006-4971, (20131115), page 2336, (20210707), XP086749020 [Y] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood.V122.21.2336.2336
 [Y]  - SIVARAM PILLARISETTI ET AL, "A multimodal disease modifying approach to treat neuropathic pain - inhibition of soluble epoxide hydrolase (sEH)", DRUG DISCOVERY TODAY, AMSTERDAM, NL, (20151101), vol. 20, no. 11, doi:10.1016/j.drudis.2015.07.017, ISSN 1359-6446, pages 1382 - 1390, XP055423710 [Y] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.drudis.2015.07.017
International search[Y]JPH05176782  (TAISHO PHARMA CO LTD) [Y] 1-16* claims, examples *;
 [Y]WO2007040082  (UNIV TOKYO NAT UNIV CORP [JP], et al) [Y] 1-16 * claims, examples 1-2 *;
 [Y]WO2010110026  (UNIV TOKYO NAT UNIV CORP [JP], et al) [Y] 1-16 * claims, paragraph [0015], examples 1-5 *;
 [Y]WO2011125930  (NIHON PHARMACEUTICAL CO LTD [JP], et al) [Y] 1-16 * claims, examples 1-8 *;
 [Y]  - KATAOKA, HITOMI et al., "Diabetes mellitus and chronic inflammation, 4. Diabetic Nephropathy and Microinflammation", TONYOBYO - JOURNAL OF THE JAPAN DIABETES SOCIETY, (20101130), vol. 54, no. 7, ISSN 0021-437X, pages 487 - 489, XP009530145 [Y] 1-16
 [Y]  - SHIBATA, KEITA et al., "Evaluation of the effects of a new series of SMTPs in the acetic acid- induced embolic cerebral infarct mouse model", European Journal of Pharmacology, (20171028), vol. 818, doi:10.1016/j.ejphar.2017.10.055, pages 221 - 227, XP085313014 [Y] 1-16 * , abstract, results, fig. 3, table 2 *

DOI:   http://dx.doi.org/10.1016/j.ejphar.2017.10.055
 [Y]  - MATSUMOTO, NAIKI et al., "Soluble Epoxide Hydrolase as an Anti-inflammatory Target of the Thrombolytic Stroke Drug SMTP-7", Journal of Biological Chemistry, (20140000), vol. 289, no. 52, doi:10.1074/jbc.M114.588087, pages 35826 - 35838, XP055640349 [Y] 1-16 * , abstract, results, fig. 1 *

DOI:   http://dx.doi.org/10.1074/jbc.M114.588087
by applicantJP2004224737
 JP2004224738
 WO2007040082
 WO2007111203
 JP2019044670
    - FEBS Letter, (19970000), vol. 418, pages 58 - 62
    - J Biol Chem, (20140000), vol. 289, pages 35826 - 35838
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.